Table 5.
ROC analysis of clinical and CMR parameters at FU1 to predict later CTRCD at FU2
| p vs T1 | CTRCD (n = 9) | No CTRCD (n = 57) | Total | Sensitivity | Specificity | Accuracy | PPV | NPV | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | AUC (95% CI) | Cutoff | TP | FN | FP | TN | (n = 66) | (%) | (%) | (%) | (%) | (%) | ||||||
| T1 | 0.712 (0.587–0.816) | –- | > 1262 ms | 9 | 0 | 32 | 25 | 66 | 100 (66–100) | 44 (31–58) | 52 (40–63) | 22 (12–37) | 100 (84–100) | |||||
| GCS | 0.712 (0.585–0.818) | 0.951 | > -17% | 6 | 3 | 14 | 41 | 64 | 67 (30–93) | 75 (61–85) | 73 (61–83) | 30 (14–52) | 93 (81–98) | |||||
| LVEF | 0.706 (0.581–0.811) | 0.956 | ≤ 60% | 7 | 2 | 18 | 39 | 66 | 78 (40–97) | 68 (55–80) | 70 (58–80) | 28 (14–48) | 95 (83–100) | |||||
| GRS | 0.671(0.542–0.783) | 0.651 | ≤ 39% | 9 | 0 | 35 | 20 | 64 | 100 (66–100) | 36 (24–50) | 45 (34–57) | 20 (11–35) | 100 (81–100) | |||||
| GLS | 0.636 (0.507–0.753) | 0.518 | > -16% | 4 | 5 | 7 | 48 | 64 | 44 (14–79) | 87 (76–95) | 81 (70–89) | 36 (15–65) | 91 (79–96) | |||||
| NT-proBNP | 0.625 (0.496–0.742) | 0.558 | ≤ 41 ng/l | 6 | 3 | 14 | 42 | 65 | 67 (35–88) | 75 (62–85) | 74 (62–83) | 30 (14–52) | 93 (81–98) | |||||
| HS TNT | 0.527 (0.399–0.652) | 0.064 | > 5 pg/ml | 6 | 3 | 30 | 25 | 65 | 67 (35–88) | 46 (34–59) | 49 (37–61) | 17 (7–32) | 90 (73–97) | |||||
| T2 | 0.513 (0.386–0.638) | 0.120 | > 45 ms | 9 | 0 | 44 | 13 | 66 | 100 (66–100) | 23 (13–36) | 33 (23–45) | 17 (9–29) | 100 (73–100) | |||||
| Combined parameter | ||||||||||||||||||
| T1 + LVEF | 0.810 (0.695–0.896) | 0.298 | > 1262 ms/ ≤ 60% | 7 | 2 | 9 | 48 | 66 | 78 (44–95) | 84 (72–92) | 83 (72–91) | 44 (23–67) | 96 (86/100) | |||||
| T1 + GRS | 0.800 (0.681–0.890) | 0.258 | > 1262 ms/ ≤ 39% | 9 | 0 | 22 | 33 | 64 | 100 (66–100) | 60 (47–72) | 66 (53–76) | 29 (13–47) | 100 (88–100) | |||||
| T1 + GCS | 0.762 (0.640–0.859) | 0.639 | > 1262 ms/ > -17% | 6 | 3 | 8 | 48 | 65 | 67 (35–88) | 86 (74–93) | 83 (72–90) | 43 (21–67) | 94 (83–99) | |||||
| T1 + GLS | 0.686 (0.558–0.796) | 0.752 | > 1262 ms/ > 16% | 4 | 5 | 4 | 51 | 64 | 44 (19–73) | 93 (82–98) | 86 (75–93) | 50 (22–78) | 91 (80/97) | |||||
| T1 + NT-proBNP | 0.690 (0.564–0.798) | 0.766 | > 1262 ms/ ≤ 41 pg/ml | 5 | 4 | 10 | 46 | 65 | 56 (27–81) | 82 (70–90) | 78 (67–87) | 33 (15–59) | 92 (81/97) | |||||
AUC, area under the curve; CI, confidence interval; GCS, global circumferential strain, GLS, global longitudinal strain, GRS, global radial strain; HS TNT, high sensitive troponin T; LVEF, left ventricular ejection fraction; FN, false negative; FP, false positive, NT-proBNP, N-terminal pro-brain natriuretic peptide; PPV, positive predictive value; NPV, negative predictive value; TP, true positive; TN, true negative; ROC, receiver operating characteristic
T1 + LVEF = > increased T1 > 1262 ms and reduced LVEF < 60%
T1 + GRS = > increased T1 > 1262 ms and reduced GRS ≤ 39%
T1 + GCS = > increased T1 > 1262 ms and reduced GCS > − 17%
T1 + GLS = > increased T1 > 1262 ms and reduced GLS > − 16%
T1 + NT-proBNP increased T1 > 1262 ms and NT-proBNP ≤ 41 ng/l